AbCellera Biologics ABCL
$9.69 −$0.78 (-7.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.73 +0.41%
Open$10.14
Prev close$10.47
Day range$9.58 – $10.26
Volume4.25M
Market cap$3.16B
P/E (TTM)–
Dividend yield–
ABCL Stock News
Headlines matching AbCellera Biologics or the ABCL ticker, most recent first.
- J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17
- JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $25
- Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13
- Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30
- Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $12
- Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $12 Positive
- Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $9 Positive
- TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
- BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15
- BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $15 Positive
- Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $30
- JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $25 Positive
- Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
- Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $12 Negative
- JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13
No comments yet — be the first to weigh in on ABCL.
Sign in to join the discussion.